Brii Bio Signs an Agreement with VBI Vaccines to Acquire BRII-179’s IP Rights
Shots:
- Brii Bio & VBI Vaccines have signed an asset purchase agreement to acquire IP rights of BRII-179 (novel recombinant protein-based HBV immunotx., expressing Pre-S1, Pre-S2 & S HBV surface antigens)
- As per the terms, Brii will acquire BRII-179’s patents, know-how & associated materials for $18M (eliminating all future milestones & royalty obligations). Prior agreements (signed in Feb 2024) will be terminated, cancelling all Brii's payment obligations except a $2.5M promissory note, on closing
- Brii is conducting BRII-179 combination studies to improve functional cure rates for chronic HBV. In addition, recruitment in P-IIb (ENRICH) study of BRII-179 followed by elebsiran & PEG-IFNα combination has been completed
Ref: Brii Biosciences | Image: Brii Biosciences & VBI Vaccines
Related News:- Brii Biosciences Report Interim Results from P-II Study of BRII-179 (VBI-2601) + PEG-IFNα for the Treatment of Chronic Hepatitis B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
